SI1928879T1 - Zlite heterociklične spojine, ki se uporabljajo kot kinazni modulatorji - Google Patents

Zlite heterociklične spojine, ki se uporabljajo kot kinazni modulatorji

Info

Publication number: SI1928879T1
Authority: SI; Slovenia
Prior art keywords: heterocyclic compounds; compounds useful; fused heterocyclic; kinase modulators; modulators
Prior art date: 2005-09-22

Application number

SI200631578T

Other languages

English (en)

Inventor

Wayne Vaccaro

Zhong Chen

Dharmpal S. Dodd

Tram N. Huynh

James Lin

Chunjian Liu

Christopher P. Mussari

John S. Tokarski

David R. Tortolani

Stephen T. Wrobleski

Original Assignee

Bristol-Myers Sqiubb Company

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-09-22

Filing date

2006-09-22

Publication date

2013-06-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37716206&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1928879(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2006-09-22 Application filed by Bristol-Myers Sqiubb Company filed Critical Bristol-Myers Sqiubb Company

2013-06-28 Publication of SI1928879T1 publication Critical patent/SI1928879T1/sl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Orthopedic Medicine & Surgery (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Hematology (AREA)
Immunology (AREA)
Oncology (AREA)
Urology & Nephrology (AREA)
Dermatology (AREA)
Pain & Pain Management (AREA)
Psychology (AREA)
Obesity (AREA)
Virology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Vascular Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Communicable Diseases (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Cardiology (AREA)

SI200631578T 2005-09-22 2006-09-22 Zlite heterociklične spojine, ki se uporabljajo kot kinazni modulatorji SI1928879T1 (sl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US71951905P	2005-09-22	2005-09-22
US11/524,996 US20070078136A1 (en)	2005-09-22	2006-09-21	Fused heterocyclic compounds useful as kinase modulators
PCT/US2006/037056 WO2007038314A2 (en)	2005-09-22	2006-09-22	Fused heterocyclic compounds useful as kinase modulators
EP06825074A EP1928879B1 (en)	2005-09-22	2006-09-22	Fused heterocyclic compounds useful as kinase modulators

Publications (1)

Publication Number	Publication Date
SI1928879T1 true SI1928879T1 (sl)	2013-06-28

Family

ID=37716206

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SI200631578T SI1928879T1 (sl)	2005-09-22	2006-09-22	Zlite heterociklične spojine, ki se uporabljajo kot kinazni modulatorji

Country Status (24)

Country	Link
US (1)	US20070078136A1 (sl)
EP (1)	EP1928879B1 (sl)
JP (1)	JP5241498B2 (sl)
KR (2)	KR20140058645A (sl)
AR (1)	AR055177A1 (sl)
AU (1)	AU2006295439B2 (sl)
BR (1)	BRPI0616393B8 (sl)
CA (1)	CA2623369C (sl)
CY (1)	CY1114001T1 (sl)
DK (1)	DK1928879T3 (sl)
EA (1)	EA017632B1 (sl)
ES (1)	ES2402664T3 (sl)
GE (1)	GEP20104943B (sl)
HR (1)	HRP20130155T1 (sl)
IL (1)	IL190280A (sl)
NO (1)	NO20081231L (sl)
NZ (1)	NZ566663A (sl)
PE (1)	PE20070520A1 (sl)
PH (1)	PH12013501329B1 (sl)
PL (1)	PL1928879T3 (sl)
PT (1)	PT1928879E (sl)
SI (1)	SI1928879T1 (sl)
TW (2)	TWI478925B (sl)
WO (1)	WO2007038314A2 (sl)

Families Citing this family (124)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PE20080538A1 (es) *	2006-08-04	2008-06-18	Takeda Pharmaceutical	Derivado heterociclico fusionado y su uso
WO2008116064A2 (en)	2007-03-21	2008-09-25	Bristol-Myers Squibb Company	Fused heterocyclic compounds useful for the treatment of proliferative, allergic, autoimmune or inflammatory diseases
AR067326A1 (es) *	2007-05-11	2009-10-07	Novartis Ag	Imidazopiridinas y pirrolo -pirimidinas sustituidas como inhibidores de cinasa de lipido
AU2008280135B2 (en) *	2007-07-26	2012-02-23	Novartis Ag	Organic compounds
JP2011504505A (ja) *	2007-11-21	2011-02-10	デコードジェネティクスイーエイチエフ	肺および心血管障害を治療するためのビアリールｐｄｅ４抑制剤
JP5529746B2 (ja) *	2007-11-21	2014-06-25	デコードジェネティクスイーエイチエフ	炎症性疾患、心臓血管疾患及び中枢神経系障害を治療するための置換されたベンゾアゾールｐｄｅ４阻害剤
ES2531396T3 (es) *	2008-01-23	2015-03-13	Bristol Myers Squibb Co	Proceso para preparar compuestos de piridinona
EP2240488B1 (en) *	2008-02-06	2016-11-02	Bristol-Myers Squibb Company	Substituted imidazopyridazines useful as kinase inhibitors
PE20091468A1 (es)	2008-02-28	2009-10-22	Novartis Ag	DERIVADOS DE 3-METIL-IMIDAZO-[1,2-b]-PIRIDAZINA
CA2716856C (en) *	2008-03-20	2013-02-19	Amgen Inc.	Aurora kinase modulators and method of use
EP2300469B1 (en) *	2008-05-13	2015-06-24	Novartis AG	Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors
WO2010036407A2 (en) *	2008-05-15	2010-04-01	Biocryst Pharmaceuticals, Inc.	Antiviral nucleoside analogs
WO2009143211A2 (en) *	2008-05-21	2009-11-26	Incyte Corporation	Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)- imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
CN102164604A (zh)	2008-07-24	2011-08-24	百时美施贵宝公司	用作激酶调节剂的稠合杂环化合物
UY32049A (es) *	2008-08-14	2010-03-26	Takeda Pharmaceutical	Inhibidores de cmet
WO2010027114A1 (en) *	2008-09-05	2010-03-11	Choongwae Pharma Corporation	Use of pyrazole-pyridine derivatives and its salts for treating or reventin osteoporosis
US8450322B2 (en)	2008-09-22	2013-05-28	Array Biopharma Inc.	Substituted imidazo[1,2b]pyridazine compounds as Trk kinase inhibitors
TWI491610B (zh) *	2008-10-09	2015-07-11	必治妥美雅史谷比公司	作為激酶抑制劑之咪唑并嗒腈
SG10201900514RA (en)	2008-10-22	2019-02-27	Array Biopharma Inc	Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors
WO2010068810A2 (en) *	2008-12-10	2010-06-17	Cgi Pharmaceuticals, Inc.	Certain substituted amides, method of making, and method of use thereof
PA8854101A1 (es) *	2008-12-18	2010-07-27	Ortho Mcneil Janssen Pharm	Derivados de imidazol bicíclicos sustituidos como moduladores de gamma secretasa
ES2443948T3 (es)	2008-12-19	2014-02-21	Bristol-Myers Squibb Company	Compuestos de carbazol carboxamida útiles como inhibidores de quinasas
JP5578490B2 (ja)	2008-12-26	2014-08-27	味の素株式会社	ピラゾロピリミジン化合物
EP2393804B1 (en) *	2009-02-06	2014-04-16	Janssen Pharmaceuticals, Inc.	Novel substituted bicyclic heterocyclic compounds as gamma secretase modulators
TWI461425B (zh)	2009-02-19	2014-11-21	Janssen Pharmaceuticals Inc	作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類
NZ596843A (en)	2009-05-07	2012-12-21	Janssen Pharmaceuticals Inc	Novel substituted indazole and aza-indazole derivatives as gamma secretase modulators
JP2012529535A (ja)	2009-06-12	2012-11-22	ブリストル−マイヤーズスクイブカンパニー	キナーゼモジュレーターとして有用なニコチンアミド化合物
AR077468A1 (es)	2009-07-09	2011-08-31	Array Biopharma Inc	Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
AU2010272578B2 (en)	2009-07-15	2015-03-05	Cellzome Limited	Substituted triazole and imidazole derivatives as gamma secretase modulators
US8389526B2 (en)	2009-08-07	2013-03-05	Novartis Ag	3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
AU2010311511B2 (en)	2009-10-30	2014-07-17	Janssen Pharmaceutica Nv	Imidazo[1,2-b]pyridazine derivatives and their use as PDE10 inhibitors
WO2011078221A1 (ja)	2009-12-24	2011-06-30	味の素株式会社	イミダゾピリダジン化合物
WO2011086099A1 (en)	2010-01-15	2011-07-21	Ortho-Mcneil-Janssen Pharmaceuticals, Inc	Novel substituted triazole derivatives as gamma secretase modulators
EP2526102B1 (en)	2010-01-22	2017-03-08	Fundación Centro Nacional de Investigaciones Oncológicas Carlos III	Inhibitors of PI3 kinase
AR080754A1 (es)	2010-03-09	2012-05-09	Janssen Pharmaceutica Nv	Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
WO2011137155A1 (en)	2010-04-28	2011-11-03	Bristol-Myers Squibb Company	Imidazopyridazinyl compounds and their uses for cancer
US20130131057A1 (en)	2010-05-13	2013-05-23	Centro Nacional De Investigaciones Oncologicas (Cnio	New bicyclic compounds as pi3-k and mtor inhibitors
WO2011146336A1 (en)	2010-05-20	2011-11-24	Array Biopharma Inc.	Macrocyclic compounds as trk kinase inhibitors
EP2582668B1 (en)	2010-06-16	2016-01-13	Bristol-Myers Squibb Company	Carboline carboxamide compounds useful as kinase inhibitors
CN103384670B (zh)	2010-07-28	2016-05-25	拜耳知识产权有限责任公司	取代的咪唑并[1,2-b]哒嗪
US8637516B2 (en)	2010-09-09	2014-01-28	Irm Llc	Compounds and compositions as TRK inhibitors
TWI541243B (zh) *	2010-09-10	2016-07-11	拜耳知識產權公司	經取代咪唑并嗒
JP2013542259A (ja)	2010-11-12	2013-11-21	ブリストル−マイヤーズスクイブカンパニー	置換アザインダゾール化合物
CN103370322B (zh)	2010-12-17	2016-02-10	拜耳知识产权有限责任公司	在过度增殖性病症的治疗中用作mps-1和tkk抑制剂的2-取代的咪唑并吡嗪
US20130303532A1 (en)	2010-12-17	2013-11-14	Bayer Intellectual Property Gmbh	Imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment hyperproliferative disorders
ES2556458T3 (es)	2010-12-17	2016-01-18	Bayer Intellectual Property Gmbh	6-Imidazopirazinas sustituidas para uso como inhibidores de Mps-1 y TKK en el tratamiento de trastornos hiperproliferativos
MX2013010970A (es)	2011-03-24	2013-10-17	Cellzome Ltd	Novedosos derivados de triazolil piperazina y triazolil piperidina sustituidos como moduladores de gamma-secretasa.
GB201108003D0 (en)	2011-05-13	2011-06-29	Materialise Dental Nv	Endodontic treatment simulation system
EP2710004A1 (en)	2011-05-17	2014-03-26	Bayer Intellectual Property GmbH	Amino-substituted imidazopyridazines as mknk1 kinase inhibitors
JP6073868B2 (ja)	2011-06-01	2017-02-01	バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒＩｎｔｅｌｌｅｃｔｕａｌＰｒｏｐｅｒｔｙＧｍｂＨ	置換アミノイミダゾピリダジン
CN103764656A (zh)	2011-06-22	2014-04-30	拜耳知识产权有限责任公司	杂环基氨基咪唑并哒嗪
CA2838645C (en)	2011-06-27	2020-03-10	Janssen Pharmaceutica Nv	1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivatives
CA2841102C (en)	2011-07-15	2019-08-13	Janssen Pharmaceuticals, Inc.	Novel substituted indole derivatives as gamma secretase modulators
CN103930422A (zh)	2011-07-19	2014-07-16	无限药品股份有限公司	杂环化合物及其用途
EP2758400A1 (en)	2011-09-23	2014-07-30	Bayer Intellectual Property GmbH	Substituted imidazopyridazines
WO2013049263A1 (en)	2011-09-27	2013-04-04	Bristol-Myers Squibb Company	Substituted bicyclic heteroaryl compounds
KR20140095513A (ko) *	2011-11-01	2014-08-01	에프. 호프만-라 로슈 아게	이미다조피리다진 화합물
MX352928B (es)	2012-01-10	2017-12-13	Hoffmann La Roche	Compuestos de piridazina-amida.
MX347917B (es)	2012-03-09	2017-05-17	Lexicon Pharmaceuticals Inc	Compuestos a base de imidazo[1,2-b]piridazina, composiciones que los comprenden, y metodos para su uso.
CA2867061A1 (en)	2012-03-14	2013-09-19	Bayer Intellectual Property Gmbh	Substituted imidazopyridazines
EA027242B1 (ru)	2012-05-16	2017-07-31	Янссен Фармасьютикалз, Инк.	ЗАМЕЩЕННЫЕ 3,4-ДИГИДРО-2H-ПИРИДО[1,2-a]ПИРАЗИН-1,6-ДИОНОВЫЕ ПРОИЗВОДНЫЕ, ПРИМЕНИМЫЕ ДЛЯ ЛЕЧЕНИЯ (В ТОМ ЧИСЛЕ) БОЛЕЗНИ АЛЬЦГЕЙМЕРА
WO2014001314A1 (en)	2012-06-26	2014-01-03	Janssen Pharmaceutica Nv	Combinations comprising pde 2 inhibitors such as 1-aryl-4-methyl- [1,2,4] triazolo [4,3-a] quinoxaline compounds and pde 10 inhibitors for use in the treatment of neurological or metabolic disorders
CA2875057C (en)	2012-07-09	2021-07-13	Janssen Pharmaceutica Nv	Imidazo[1,2-b]pyridazine and imidazo[1,2-a]pyrazine compounds and their use as inhibitors of the phosphodiesterase 10 enzyme
TW201414737A (zh)	2012-07-13	2014-04-16	必治妥美雅史谷比公司	作爲激酶抑制劑之咪唑并三□甲腈
WO2014020041A1 (en)	2012-08-02	2014-02-06	Bayer Pharma Aktiengesellschaft	Combinations for the treatment of cancer
ES2666353T3 (es)	2012-09-06	2018-05-04	Bristol-Myers Squibb Company	Inhibidores de JAK3 de imidazopiridazina y su uso para el tratamiento de enfermedades inflamatorias y autoinmunitarias
EP2920181B1 (en)	2012-11-16	2019-01-09	University Health Network	Pyrazolopyrimidine compounds
CA2889249C (en)	2012-12-20	2021-02-16	Francois Paul Bischoff	Tricyclic 3,4-dihydro-2h-pyrido[1,2-a]pyrazine-1,6-dione derivatives as gamma secretase modulators
EP2935272B1 (en)	2012-12-21	2017-02-22	Bristol-Myers Squibb Company	Pyrazole substituted imidazopyrazines as casein kinase 1 d/e inhibitors
JP6267231B2 (ja)	2012-12-21	2018-01-24	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	カゼインキナーゼ１δ／ε阻害剤としての新規な置換イミダゾール
JP6283691B2 (ja)	2013-01-17	2018-02-21	ヤンセンファーマシューティカエヌ．ベー．	γセクレターゼ調節剤としての新規な置換ピリド−ピペラジノン誘導体
US9249163B2 (en)	2013-06-11	2016-02-02	Janssen Pharmaceutica Nv.	PDE10a inhibitors for the treatment of type II diabetes
WO2014198647A2 (en)	2013-06-11	2014-12-18	Bayer Pharma Aktiengesellschaft	Prodrug derivatives of substituted triazolopyridines
WO2014200882A1 (en)	2013-06-11	2014-12-18	Janssen Pharmaceutica Nv	PDE10a INHIBITORS FOR THE TREATMENT OF TYPE II DIABETES
AR096721A1 (es)	2013-06-25	2016-01-27	Bristol Myers Squibb Co	Compuestos de tetrahidrocarbazol y carbazol carboxamida sustituidos
KR102345381B1 (ko)	2013-06-25	2021-12-29	브리스톨-마이어스 스큅 컴퍼니	키나제 억제제로서 유용한 카르바졸 카르복스아미드 화합물
US9453002B2 (en)	2013-08-16	2016-09-27	Janssen Pharmaceutica Nv	Substituted imidazoles as N-type calcium channel blockers
AR097543A1 (es) *	2013-09-06	2016-03-23	Lexicon Pharmaceuticals Inc	COMPUESTOS BASADOS EN IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO
WO2015089143A1 (en) *	2013-12-10	2015-06-18	Bristol-Myers Squibb Company	Imidazopyridazine compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
US9969687B2 (en)	2013-12-23	2018-05-15	Norgine B.V.	Compounds useful as CCR9 modulators
US10562897B2 (en)	2014-01-16	2020-02-18	Janssen Pharmaceutica Nv	Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators
TW201613927A (en)	2014-09-01	2016-04-16	Bayer Pharma AG	Method for preparation of substituted imidazopyridazines
EA034931B1 (ru)	2014-10-24	2020-04-08	Бристол-Майерс Сквибб Компани	Индолкарбоксамидные соединения
EP3699181B1 (en)	2014-11-16	2023-03-01	Array Biopharma, Inc.	Crystalline form of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
KR101635173B1 (ko)	2014-12-03	2016-06-30	충남직물공업협동조합	디지털프린팅 날염 친환경 자카드직물의 제조방법 및 그 직물
CN107108633B (zh)	2014-12-19	2020-05-12	詹森药业有限公司	作为PI3Kβ抑制剂的杂环基连接的咪唑并哒嗪衍生物
HUE045220T2 (hu)	2014-12-19	2019-12-30	Janssen Pharmaceutica Nv	Imidazopiridazin-származékok mint PI3Kbéta inhibitorok
CN107530329B (zh)	2015-03-09	2021-10-08	奥瑞基尼探索技术有限公司	用作CDK抑制剂的吡唑并[1，5-a][1，3，5]三嗪和吡唑并[1，5-a]嘧啶衍生物
ES2928164T3 (es)	2015-10-19	2022-11-15	Incyte Corp	Compuestos heterocíclicos como inmunomoduladores
KR20180102544A (ko)	2015-10-26	2018-09-17	더 리전츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코퍼레이트	Trk 억제제-내성 암에서의 점 돌연변이 및 이의 관련 방법
MY199220A (en)	2015-11-19	2023-10-20	Incyte Corp	Heterocyclic compounds as immunomodulators
BR112018012756A2 (pt)	2015-12-22	2018-12-04	Incyte Corp	compostos heterocíclicos como imunomoduladores
ES2987474T3 (es)	2016-04-04	2024-11-15	Loxo Oncology Inc	Formulaciones líquidas de (S)-N-(5-((R)-2-(2,5-difluorofenil)-pirrolidin-1-IL)-pirazolo[1,5-A]pirimidin-3-IL)-3-hidroxipirrolidina-1-carboxamida
US10045991B2 (en)	2016-04-04	2018-08-14	Loxo Oncology, Inc.	Methods of treating pediatric cancers
TW201808950A (zh)	2016-05-06	2018-03-16	英塞特公司	作為免疫調節劑之雜環化合物
RU2745953C2 (ru)	2016-05-18	2021-04-05	Локсо Онколоджи, Инк.	Способ получения (s)-n-(5-((r)-2-(2,5-дифторфенил)пирролидин-1-ил)-пиразоло[1,5-a]пиримидин-3-ил)-3-гидроксипирролидин-1-карбоксамида и его солей
ES2905980T3 (es)	2016-05-26	2022-04-12	Incyte Corp	Compuestos heterocíclicos como inmunomoduladores
WO2017210399A1 (en) *	2016-06-02	2017-12-07	Celgene Corporation	Animal and human anti-malarial agents
SG10202012828TA (en)	2016-06-20	2021-01-28	Incyte Corp	Heterocyclic compounds as immunomodulators
MA45669A (fr)	2016-07-14	2019-05-22	Incyte Corp	Composés hétérocycliques utilisés comme immunomodulateurs
EP3504198B1 (en)	2016-08-29	2023-01-25	Incyte Corporation	Heterocyclic compounds as immunomodulators
JOP20190092A1 (ar)	2016-10-26	2019-04-25	Array Biopharma Inc	عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
JP7012082B2 (ja) *	2016-11-17	2022-01-27	ブリストル－マイヤーズスクイブカンパニー	Ｉｌ－１２、ｉｌ－２３および／またはｉｆｎ－アルファのイミダゾピリダジン調節剤
EP3554257B1 (en)	2016-12-15	2023-07-12	Société des Produits Nestlé S.A.	Compositions and methods that modulate white blood cells or neutrophils in a companion animal
WO2018119236A1 (en)	2016-12-22	2018-06-28	Incyte Corporation	Triazolo[1,5-a]pyridine derivatives as immunomodulators
IL295660A (en)	2016-12-22	2022-10-01	Incyte Corp	Benzooxazole derivatives as immunomodulators
MA47120A (fr)	2016-12-22	2021-04-28	Incyte Corp	Dérivés pyridine utilisés en tant qu'immunomodulateurs
JOP20190213A1 (ar)	2017-03-16	2019-09-16	Array Biopharma Inc	مركبات حلقية ضخمة كمثبطات لكيناز ros1
DK3606926T3 (da)	2017-04-05	2021-07-05	Curovir Ab	Heteroaromatiske forbindelser anvendelige i terapi
EP3612030A4 (en) *	2017-04-21	2021-04-28	Ikena Oncology, Inc.	AHR INDOLE INHIBITORS AND THEIR USES
US11759466B2 (en)	2018-03-01	2023-09-19	The Johns Hopkins University	Inhibition of nSMase for the treatment of human immunodeficiency virus infection
EP4212529B1 (en)	2018-03-30	2025-01-29	Incyte Corporation	Heterocyclic compounds as immunomodulators
EP4219492B1 (en)	2018-05-11	2024-11-27	Incyte Corporation	Heterocyclic compounds as immunomodulators
US20210121462A1 (en) *	2018-07-27	2021-04-29	Cocrystal Pharma, Inc.	Pyrrolo[2,3-b]pyridin derivatives as inhibitors of influenza virus replication
EP3914357A4 (en) *	2019-01-23	2022-10-12	Nimbus Lakshmi, Inc.	TYK2 INHIBITORS AND THEIR USES
EP3935058B1 (en) *	2019-03-05	2024-08-21	Bristol-Myers Squibb Company	Imidazopyridazine compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
WO2021030162A1 (en)	2019-08-09	2021-02-18	Incyte Corporation	Salts of a pd-1/pd-l1 inhibitor
MX2022003578A (es)	2019-09-30	2022-05-30	Incyte Corp	Compuestos de pirido[3,2-d]pirimidina como inmunomoduladores.
IL292524A (en)	2019-11-11	2022-06-01	Incyte Corp	Salts and crystalline forms of a pd-1/pd-l1 inhibitor
IL302590A (en)	2020-11-06	2023-07-01	Incyte Corp	Process for making a pd-1/pd-l1 inhibitor and salts and crystalline forms thereof
US11780836B2 (en)	2020-11-06	2023-10-10	Incyte Corporation	Process of preparing a PD-1/PD-L1 inhibitor
US11760756B2 (en)	2020-11-06	2023-09-19	Incyte Corporation	Crystalline form of a PD-1/PD-L1 inhibitor
KR20220170766A (ko) *	2021-06-22	2022-12-30	주식회사 엘지화학	단백질 키나아제 억제제로서의 신규한 화합물
EP4268824A1 (en) *	2022-04-26	2023-11-01	Manros Therapeutics	Imidazo[2,1-f][1,2,4]triazine derivatives useful as a medicament

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4166851A (en)	1977-05-16	1979-09-04	Merck & Co., Inc.	Certain imidazo(1,2a)pyridine derivatives
CH635587A5 (fr) *	1978-01-09	1983-04-15	Aron Sa	Derives amines de pyrazolo (1,5-a) s.triazine, therapeutiquement actifs et leurs procedes de preparation.
FR2619818B1 (fr) *	1987-09-01	1990-01-12	Sanofi Sa	Imidazo (1,2-b) pyridazines, procede pour leur preparation et compositions pharmaceutiques les contenant
US5260285A (en)	1990-12-07	1993-11-09	Merck & Co., Inc.	Substituted imidazopyridazines as angiotensin II antagonists
DE4327027A1 (de)	1993-02-15	1994-08-18	Bayer Ag	Imidazoazine
ATE340176T1 (de) *	1996-08-28	2006-10-15	Pfizer	Substituierte 6,5-heterobicyclische-derivate
WO2002050079A1 (fr) *	2000-12-20	2002-06-27	Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.)	Inhibiteurs de kinases dependantes des cylines (cdk) et de la glycogene synthase kinase-3 (gsk-3)
FR2850653A1 (fr) *	2003-02-04	2004-08-06	Univ Pasteur	Derives de pyrazolotriazine, procede de preparation et utilisations
AU2004215481B2 (en) *	2003-02-28	2010-11-11	Teijin Pharma Limited	Pyrazolo(1,5-A)pyrimidine derivatives
DE10356579A1 (de) *	2003-12-04	2005-07-07	Merck Patent Gmbh	Aminderivate
TW200536536A (en)	2004-02-25	2005-11-16	Schering Corp	Pyrazolotriazines as kinase inhibitors
US7537840B2 (en) *	2004-08-05	2009-05-26	H.B. Licensing & Financing, Inc.	Polyamide adhesive and articles including the same
EP1879896A1 (en) *	2005-04-05	2008-01-23	Eli Lilly And Company	Imidazopyridazine compounds

2006
- 2006-09-21 US US11/524,996 patent/US20070078136A1/en not_active Abandoned
- 2006-09-22 PL PL06825074T patent/PL1928879T3/pl unknown
- 2006-09-22 AU AU2006295439A patent/AU2006295439B2/en not_active Ceased
- 2006-09-22 WO PCT/US2006/037056 patent/WO2007038314A2/en active Application Filing
- 2006-09-22 TW TW102124973A patent/TWI478925B/zh not_active IP Right Cessation
- 2006-09-22 TW TW095135141A patent/TWI441825B/zh not_active IP Right Cessation
- 2006-09-22 SI SI200631578T patent/SI1928879T1/sl unknown
- 2006-09-22 NZ NZ566663A patent/NZ566663A/en not_active IP Right Cessation
- 2006-09-22 CA CA2623369A patent/CA2623369C/en active Active
- 2006-09-22 KR KR1020147007661A patent/KR20140058645A/ko not_active Withdrawn
- 2006-09-22 JP JP2008532430A patent/JP5241498B2/ja not_active Expired - Fee Related
- 2006-09-22 DK DK06825074.5T patent/DK1928879T3/da active
- 2006-09-22 PE PE2006001149A patent/PE20070520A1/es active IP Right Grant
- 2006-09-22 KR KR1020087009516A patent/KR101399766B1/ko not_active Expired - Fee Related
- 2006-09-22 GE GEAP200610649A patent/GEP20104943B/en unknown
- 2006-09-22 EP EP06825074A patent/EP1928879B1/en active Active
- 2006-09-22 BR BRPI0616393A patent/BRPI0616393B8/pt not_active IP Right Cessation
- 2006-09-22 PT PT68250745T patent/PT1928879E/pt unknown
- 2006-09-22 EA EA200800873A patent/EA017632B1/ru not_active IP Right Cessation
- 2006-09-22 ES ES06825074T patent/ES2402664T3/es active Active
- 2006-09-25 AR ARP060104153A patent/AR055177A1/es active Pending
2008
- 2008-03-10 NO NO20081231A patent/NO20081231L/no not_active Application Discontinuation
- 2008-03-18 IL IL190280A patent/IL190280A/en active IP Right Grant
2013
- 2013-02-25 HR HRP20130155TT patent/HRP20130155T1/hr unknown
- 2013-05-09 CY CY20131100374T patent/CY1114001T1/el unknown
- 2013-06-21 PH PH12013501329A patent/PH12013501329B1/en unknown

Also Published As

Publication number	Publication date
GEP20104943B (en)	2010-04-12
WO2007038314A2 (en)	2007-04-05
PH12013501329B1 (en)	2019-11-08
WO2007038314A3 (en)	2007-07-12
US20070078136A1 (en)	2007-04-05
CA2623369C (en)	2014-11-18
AU2006295439A1 (en)	2007-04-05
TW200804385A (en)	2008-01-16
TW201350488A (zh)	2013-12-16
TWI478925B (zh)	2015-04-01
PT1928879E (pt)	2013-04-15
KR20080063344A (ko)	2008-07-03
DK1928879T3 (da)	2013-05-21
EP1928879B1 (en)	2013-02-13
IL190280A0 (en)	2009-09-22
EA200800873A1 (ru)	2008-08-29
PE20070520A1 (es)	2007-08-29
CY1114001T1 (el)	2016-07-27
BRPI0616393B8 (pt)	2021-05-25
NZ566663A (en)	2011-03-31
EA017632B1 (ru)	2013-02-28
JP5241498B2 (ja)	2013-07-17
NO20081231L (no)	2008-04-16
PH12013501329A1 (en)	2014-08-27
BRPI0616393B1 (pt)	2020-03-24
BRPI0616393A2 (pt)	2011-06-21
TWI441825B (zh)	2014-06-21
ES2402664T3 (es)	2013-05-07
IL190280A (en)	2013-08-29
JP2009509961A (ja)	2009-03-12
HRP20130155T1 (hr)	2013-03-31
EP1928879A2 (en)	2008-06-11
KR101399766B1 (ko)	2014-06-18
CA2623369A1 (en)	2007-04-05
KR20140058645A (ko)	2014-05-14
PL1928879T3 (pl)	2013-07-31
AR055177A1 (es)	2007-08-08
AU2006295439B2 (en)	2012-09-13

Publication	Publication Date	Title
IL190280A0 (en)	2009-09-22	Fused heterocyclic compounds useful as kinase modulators
TWI370820B (en)	2012-08-21	Fused heterocyclic compounds
HK1123038A1 (en)	2009-06-05	Heterocyclic compounds
IL191768A0 (en)	2008-12-29	Novel fused pyrrole derivatives
EP2162132A4 (en)	2013-01-16	Heterocyclic kinase modulators
IL179414A0 (en)	2007-05-15	Fused heterocyclic compound
IL180587A0 (en)	2007-06-03	Heterocyclic compounds
PL1919907T3 (pl)	2011-07-29	Związek heterocykliczny
ZA200709051B (en)	2008-10-29	Heterocyclic compound
ZA200805338B (en)	2010-03-31	Heterocyclic derivatives as modulators of ion channels
IL187686A0 (en)	2008-08-07	Aminopyrimidines as kinase modulators
IL187693A0 (en)	2008-08-07	Aminopyrimidines as kinase modulators
IL180325A0 (en)	2007-07-04	Fused heterocyclic kinase inhibitors
EP1885369A4 (en)	2010-04-14	FUSED HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF AND USES THEREOF
IL190450A0 (en)	2008-11-03	Substituted pyrazole compounds
IL195158A0 (en)	2009-08-03	Novel heterocyclic compounds
IL194815A0 (en)	2009-08-03	Fused heterocyclic compounds and their use as mglur5 modulators
ZA200610780B (en)	2008-11-26	Fused heterocyclic kinase inhibitors
IL183647A (en)	2013-06-27	The heterocyclic compounds are converted into 3-ethylidenehydrazino
IL191191A0 (en)	2009-08-03	Pharmaceutical compositions containing fused heterocyclic compounds
ZA200805241B (en)	2009-03-25	Heterocyclic GABAB modulators
ZA200802549B (en)	2010-03-31	Fused heterocyclic compounds useful as kinase modulators
EP1737446A4 (en)	2010-05-26	CONDENSED HETEROCYCLIC COMPOUNDS
ZA200700162B (en)	2009-09-30	Novel heterocyclic compounds
EP1961754A4 (en)	2009-11-11	BICYCLIC HETEROCYCLIC COMPOUND